Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (588)	12/18/2003 10:33:47 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 1022

XOMA continues to play on strength, the realm of Butch Dellio..... operations/production, and they continue to highlight their weakness, R&D. These 25% or 30% deals are great.

To: Icebrg who wrote (588)	12/22/2003 2:07:26 AM
From: Icebrg	Read Replies (2) \| Respond to of 1022

MorphoSys Enters Antibody Collaboration With Pfizer Monday December 22, 1:47 am ET Edited Press Release FRANKFURT -(Dow Jones)- MorphoSys AG said Monday it has entered into a collaboration with Pfizer Inc (NYSE:PFE - News) for the development of therapeutic antibodies. MorphoSys will use its HuCAL GOLD library to generate therapeutic antibodies against multiple targets from Pfizer. Pfizer will carry out the preclinical and clinical development and the subsequent marketing of resultant products. MorphoSys will receive an upfront payment, which will further strengthen its cash position, and, for each antibody developed in the collaboration, research support and milestone payments. In addition, MorphoSys stands to receive royalty payments, on any antibody products coming out of the collaboration. The potential value to MorphoSys in committed funding and potential developmental milestone payments on future products is in excess of US$ 50 million, not including royalties. During the five-year term of the agreement, MorphoSys will use its HuCAL GOLD antibody technology to select and optimize fully human antibodies against disease targets from Pfizer. MorphoSys brings its expertise in the high- throughput selection and subsequent optimization of fully human antibodies fulfilling predefined criteria to combine with Pfizer's capabilities for disease target identification and clinical development.